Overview

Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Status:
Completed

Trial end date:
2021-06-25

Target enrollment:

Participant gender:

Summary

This is an open label, multicenter, adaptive Phase 2 clinical study. The study will consist of a screening period, a treatment period, an end of treatment visit, and a follow-up period.

Phase:

Phase 2

Details

Lead Sponsor:

Debiopharm International SA
ImmunoGen, Inc.

Treatments:

Rituximab